Summary
No clear evidence that thymosin α1 decreases 28-day all-cause mortality in adults with sepsis. 28-day mortality was 23.4% in thymosin α1 group vs 24.1% in placebo (HR 0.99, p=0.93).
Study Details
Study Design
Multicentre, double-blind, randomized, placebo-controlled phase 3 trial
Indication
Sepsis
Intervention
Thymosin alpha-1
Species
Human
Sample Size
1,106 subjects
Tags
SourceRCTThymalfasinSepsisTestsBMJ